Landmark Trial: A Statin Cut Major Heart Events 30% in Healthy Adults Over 70

Should healthy people in their seventies take a statin to prevent a first heart attack or stroke? The STAREE trial offers the clearest answer yet, and it is genuinely two-sided.

STAREE (STAtin therapy for Reducing Events in the Elderly) — the first large primary-prevention statin trial focused on older adults — found atorvastatin reduced major cardiovascular events by about 30% versus placebo over roughly six years in community-dwelling adults aged 70 and over with no prior cardiovascular disease. Results were presented at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

Why this trial was needed

Statins are among the most studied drugs in medicine, and older adults have been systematically underrepresented in the trials establishing their benefit — particularly for primary prevention, meaning people who have not yet had a cardiovascular event.

The evidence base therefore left clinicians extrapolating: taking results from 55-year-olds and assuming they apply at 78. That assumption is not obviously safe. Older adults metabolise drugs differently, take more other medications, experience more side effects, and — critically — face competing risks. Someone at 80 may die of something else before a prevented heart attack would have occurred, which mathematically shrinks the benefit available.

The efficacy result

A 30% reduction in major cardiovascular events is substantial and consistent with what statins achieve in younger populations. In absolute terms it matters more here, because older adults have a much higher baseline event rate — the same relative reduction prevents more events per person treated.

The benefit was driven mainly by nonfatal events. That is not a dismissal: a nonfatal stroke can mean permanent disability and loss of independence, which for many older adults is the outcome they fear most.

The finding that complicates it

Disability-free survival did not differ significantly between the statin and placebo groups.

This is the result that deserves the most attention, and it reflects an endpoint chosen deliberately. For older adults, the relevant question is frequently not how long they live but how long they remain independent — able to manage their own affairs and daily activities.

A trial can reduce cardiovascular events by 30% and leave that measure unchanged if disability in this population is driven substantially by things statins do not touch: dementia, frailty, falls, arthritis, cancer, sensory loss. Preventing some heart attacks helps, and it does not alter the broader trajectory of ageing.

Both results are true simultaneously, and which one matters more depends on what an individual patient is trying to achieve.

The side effects were real

Muscle, liver and diabetes-related adverse events were more common with atorvastatin, though serious adverse events were balanced overall.

Muscle symptoms matter disproportionately in this age group. Weakness and aching that would be an annoyance at 50 can contribute to reduced activity, deconditioning and falls at 80 — and falls are a major cause of the disability and loss of independence the trial was measuring.

The diabetes signal is a known statin effect, and adds a monitoring requirement in a population often already managing multiple conditions.

The time-to-benefit problem

One framing not captured in headline results is worth applying. Preventive therapies take time to produce benefit — a statin does not prevent an event next month, but over years of reduced plaque progression.

That time horizon has to be compared against remaining life expectancy. For a healthy 72-year-old with many years ahead, a six-year benefit is clearly relevant. For an 86-year-old with several serious conditions, the arithmetic changes: the side effects arrive immediately and the benefit may not arrive at all. STAREE enrolled community-dwelling adults, who are healthier than the general older population, and results should not be extended to frail patients.

An instructive parallel

This is not the first time a preventive therapy assumed to work in older adults has been tested properly. A large trial of low-dose aspirin for primary prevention in healthy older people found no benefit on disability-free survival and increased bleeding, substantially changing practice.

STAREE is a considerably more favourable result — the cardiovascular benefit is real. But the pattern is the same: assumptions extrapolated from younger populations require testing, and the answer is frequently more nuanced than expected.

What it means in practice

STAREE provides real evidence that primary-prevention statins reduce cardiovascular events in adults over 70, while underscoring that the decision should weigh that benefit against side effects and individual goals.

What this changes about deprescribing

STAREE speaks to a question clinicians face constantly and had almost no evidence for: whether to stop a statin in an older patient already taking one.

Deprescribing has gained momentum as a discipline, driven by recognition that older adults accumulate medications over decades and that the balance of benefit and harm for each shifts with age. Statins have been a frequent candidate for review, precisely because the evidence in the very old was so thin that continuing them rested largely on inertia.

This trial complicates the case for routine withdrawal. A 30% reduction in cardiovascular events is not a benefit to discard casually, and while it applies to starting rather than continuing therapy, the underlying biology is the same. Equally, the absence of a disability-free survival difference means continuation cannot be defended as protecting independence. The honest conclusion is that the decision genuinely depends on what the patient is optimising for — which is a less satisfying answer than either camp wanted.

That is genuinely a shared decision rather than a rule. A patient prioritising avoiding a stroke and a patient prioritising avoiding new medications and their effects can look at the same trial and reasonably reach different conclusions. This summarises a clinical trial and is not medical advice; decisions about statins should be made with a clinician.